+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Development and testing of a patient-derived questionnaire for treatment of neovascular age-related macular degeneration: dimensions of importance in treatment of neovascular age-related macular degeneration



Development and testing of a patient-derived questionnaire for treatment of neovascular age-related macular degeneration: dimensions of importance in treatment of neovascular age-related macular degeneration



Acta Ophthalmologica 96(8): 804-811



Studies reporting on patient perspectives during treatment of neovascular age-related macular degeneration (nAMD) are limited. Thus, the aim of this study was to develop and test psychometric performance of a patient-derived questionnaire to capture important experiences during intravitreal treatment. Patients (n = 44) with at least 3-month experience of intravitreal injection treatment for nAMD identified the dimensions of priority and also performed a weighting procedure to develop a score for comparison. The questionnaire comprised two versions: one focusing on the relative importance' of the dimensions and one on the experience of the 'management' during treatment. The questionnaire was then tested for psychometric performance in a longitudinal design in newly diagnosed patients at baseline (n = 197), after three (n = 184) and six (n = 150) months of treatment. Of the 15 included dimensions, the following were most frequently reported: 'receive treatment to preserve vision', 'information', 'waiting time', 'trust' and 'accommodating staff. The psychometric testing showed moderate reliability (intraclass correlation coefficient: 0.65-0.67) for the two versions and high level of face validity (8.3). The dimensions, 'preserving vision', 'early access to treatment', 'pain relief', 'information about the treatment/diagnosis' and 'visual aids' were consistently reported higher in 'importance' than in 'management', at both 3 and 6 months, indicating a potential for improvement in clinical practice for these dimensions. This study provides a brief patient-derived questionnaire, expressed with a score with good psychometric performance that can be used for monitoring during intravitreal injection treatment of nAMD patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065751454

Download citation: RISBibTeXText

PMID: 30198182

DOI: 10.1111/aos.13847


Related references

Effect of Intraocular Pressure-Lowering Medications on Neovascular Age-Related Macular Degeneration Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatment Trials. Retina 39(4): 636-647, 2019

Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 123(8): 1751-1761, 2016

Assessment of retinal vessel caliber changes in eyes with non-neovascular age-related macular degeneration after progression to neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology 254(3): 599-601, 2016

Anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: Comparison of Age-related Macular Degeneration Treatments Trials 5 year outcomes and implication for clinical practice. Clinical and Experimental Ophthalmology 45(4): 333-335, 2017

Treatment of age-related neovascular macular degeneration: the patient's perspective. Graefe's Archive for Clinical and Experimental Ophthalmology 255(11): 2237-2246, 2017

Correlation between cystoid macular edema and fluorescein angiography characteristics of choroidal neovascular membranes in patients with new subfoveal neovascular age-related macular degeneration. IOVS 42(4): S229, 2001

Prognosis and treatment of macular bleeding in neovascular age-related macular degeneration. Der Ophthalmologe 114(5): 476-480, 2017

Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. Biodrugs 21(4): 245-257, 2007

Visual acuity and contrast sensitivity in patients with neovascular age-related macular degeneration. Results from the Radiation Therapy for Age-Related Macular Degeneration (RAD-) Study. Graefe's Archive for Clinical and Experimental Ophthalmology 241(12): 968-974, 2003

Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration. Acta Ophthalmologica 94(8): E757-E764, 2016

Patient Preferences in the Treatment of Neovascular Age-Related Macular Degeneration: A Discrete Choice Experiment. Ophthalmology 123(4): 876-883, 2016

Patient-Reported Treatment Satisfaction with Stereotactic Radiotherapy in Neovascular Age-Related Macular Degeneration. Klinische Monatsblatter für Augenheilkunde 236(7): 892-900, 2019

Patient Preferences In The Treatment of Neovascular Age-Related Macular Degeneration: A Discrete Choice Experiment. Value in Health 19(7): A571-A572, 2016

Bevacizumab and ranibizumab for neovascular age-related macular degeneration: a treatment approach based on individual patient needs. Canadian Journal of Ophthalmology. Journal Canadien d'Ophtalmologie 47(2): 165-169, 2012

Patient characteristics and treatment of neovascular age-related macular degeneration in France: the LUEUR1 observational study. Graefe's Archive for Clinical and Experimental Ophthalmology 249(4): 521-527, 2011